Original news and analysis on international IP policy
Members of the World Intellectual Property Organization patent law committee this week bridged significant differences and agreed on a range of activities for future work, each with their own goals for the international patent system in mind.
Following news reports that pharmaceutical producer AstraZeneca will end its spending on early stage research and development for tuberculosis, malaria and neglected tropical diseases, Médecins Sans Frontières issued a statement saying the move is further proof that substantive change to the global pharmaceutical R&D system is needed.
A new pharmaceutical industry-backed study draws attention to the value of innovative medicines in reducing healthcare costs and to the wider society that goes beyond clinical and personal values. However, in middle income countries, national prioritisation and improvements in healthcare infrastructure are needed to maximise the value of medicinal innovation, the study found.
The recent World Intellectual Property Organization Conference on Open Innovation: Collaborative Projects and the Future of Knowledge showed the potential of open collaborative innovation in confronting some of today’s greatest challenges. This model of innovation is used in industries ranging from health research and solutions to climate change to film production and museum design.
In the annual State of the Union speech of the United States president to Congress last night, President Obama described an innovation race, and highlighted the importance of trade agreements and passage of patent reform legislation.
An important international platform that has seen stark differences in the past, the World Intellectual Property Organization Standing Committee on the Law of Patents (SCP) began a weeklong meeting today on improving the patent system with parties promoting their own interests and asking straightforward questions of others.
Members of the World Health Organization Executive Board this week moved forward on the long path to new ways to spur research and development for diseases that mainly afflict poor populations. A process has been set for considering – and potentially choosing among - eight projects before the annual World Health Assembly in May.
The sometimes tense issue of intellectual property rights flexibilities built into international trade rules on IP briefly threatened to trip up a proposal on access to medicines today at the World Health Organization. But members managed to steer the debate to consensus on a text that will now head to the full membership for approval in May.
Discussions on access to essential medicines yesterday at the World Health Organization were in some ways overshadowed by the recent leak of a global pharmaceutical campaign aimed at derailing efforts by the South African government to revise its intellectual property policy. WHO Director General Margaret Chan strongly supported South Africa, as did several developing countries, while developed countries remained silent on the subject.
Daniele Dionisio writes: Hopes that a comprehensive global health goal could be reached by 2035 are hardly credible with the load of unresolved issues still on the table. This article turns the spotlight on much-debated relevant questions that were left out or under-scrutinised in a recently published Lancet report.
Several health care organisations this week signed a “consensus framework" for ethical collaboration between patients’ organisations, healthcare professionals, and the pharmaceutical industry.
The South African minister leading the charge in drafting a revised intellectual property policy for the country has expressed his dismay at reports of a pharmaceutical company campaign aimed at derailing the process of implementing the new IP policy.